Fig. 1From: Comparative effectiveness and cost evaluation of Risankizumab and Adalimumab in the management of psoriasis: a real-world study in Saudi ArabiaThe relationship between baseline and follow-up PASI scores for Adalimumab (ADA) and Risankizumab (RZB)Back to article page